Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 27% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Harmony Biosciences Holdings, Inc. (HRMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Harmony Biosciences Holdings, Inc. ever had a stock split?
Harmony Biosciences Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey Dayno CEO | NASDAQ (NMS) Exchange | 413197104 CUSIP |
| US Country | 268 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company dedicated to the development and commercialization of unique therapies for patients suffering from rare and other neurological diseases within the United States. Initially known as Harmony Biosciences II, Inc., the company underwent a name change to Harmony Biosciences Holdings, Inc. in February 2020. Founded in 2017, Harmony Biosciences has established its headquarters in Plymouth Meeting, Pennsylvania, signifying its commitment to addressing unmet medical needs in the neurology space through innovative research and therapeutic solutions.
Products and Services
- WAKIX (pitolisant)
- HBS-102
Harmony Biosciences offers WAKIX (pitolisant), which is a pioneering molecule known for its novel mechanism of action. It is specifically designed for the treatment of excessive daytime sleepiness in adult patients suffering from narcolepsy. This product marks a significant advancement in narcolepsy treatment, offering a new hope and improved quality of life for patients grappling with this chronic sleep disorder.
Another significant therapeutic solution in Harmony Biosciences' portfolio is HBS-102, which targets the melanin-concentrating hormone receptor 1 for MCH neurons. This product represents the company's ongoing commitment to exploring new pathways and mechanisms to address neurological disorders with unmet medical needs. While still under development, HBS-102 underscores Harmony Biosciences’ dedication to expanding its offerings and making impactful contributions to the field of neurology.
